Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Jurnal Cahaya Mandalika Asian Journal of Health Research
Albab, Chabib Fachry
Unknown Affiliation
Humanities Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Systematic Review & Meta-Analysis Triple Inhaler Therapy Outperforms Dual Therapy in Moderate to Severe COPD: A Meta-Analysis of 11,477 Patients from 4 Randomized Controlled Trials Shows Improved Lung Function, Reduced Exacerbations, and Comparable Safety Profile Albab, Chabib Fachry; Habibah, Almas Talida; Wulandhari; Murteza, Faiq; Mas'udi, Achmad Fayyad
Asian Journal of Health Research Vol. 4 No. 1 (2025): Volume 4 No 1 (April) 2025
Publisher : Ikatan Dokter Indonesia Wilayah Jawa Timur

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55561/ajhr.v4i1.224

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) continues to be one of the most prevalent health conditions globally. Treatment strategies for COPD are often tailored to disease severity, beginning with single therapy and advancing to dual or triple therapy as needed. However, limited randomized controlled trials (RCTs) have explored the comparative impact of dual and triple inhaler therapies on clinical outcomes and exacerbation frequencies. Our meta-analysis aims to evaluate the effectiveness and safety of triple and double medication in moderate and severe COPD patients.    Material and Methods: A comprehensive exploration of databases was conducted to identify RCTs comparing triple and dual inhaler therapies. For binary outcomes, the pooled RR or OR was calculated; we also used weighted MD to analyze continuous outcomes, both with high CI (95%).    Results: The meta-analysis included four RCTs involving 13,574 patients, of whom 67.92% were male. Triple inhaler therapy proves lung function improvements significantly, evidenced by an increase in FEV1 (MD: 0.06; 95% CI: 0.01–0.11; p=0.02). It showed significant association with a exacerbations reduction in both moderate and severe one (RR: 0.76; 95% CI: 0.72–0.81; p<0.000001). No notable differences in adverse events were observed between combination of triple and double medication (OR: 0.99; 95% CI: 0.90–1.10; p=0.85).    Conclusion: Triple inhaler medication proves more effective than double medication in moderate and severe COPD patients, enhancing lung function and lowering exacerbation rates without a significant increase in adverse effects.
THE EFFECT OF ORLISTAT ADMINISTRATION IN HbA1c, WEIGHT LOSS AND FASTING BLOOD GLUCOSE (FBG) OF OBESITY OR OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META ANALYSIS Albab, Chabib Fachry; Habibah, Almas Talida; El-Ma’i, Zaha; Hanifullah, Ardan Mulyarajasa; Permatasari, Azmil
Jurnal Cahaya Mandalika ISSN 2721-4796 (online) Vol. 3 No. 3: Jurnal Cahaya Mandalika
Publisher : Institut Penelitian Dan Pengambangan Mandalika Indonesia (IP2MI)

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Orlistat has unique mechanism of action in the pharmacological agents for obesity management in patients with type 2 diabetes mellitus (T2DM). This meta-analysis was to consolidate the existing body of evidence regarding the effect of Orlistat administration on HbA1c levels, weight loss, and fasting blood glucose (FBG) levels in patients who are both obese or overweight and diagnosed with T2DM. The method used in this study was systematic review and meta-analysis which literature search was carried out using PubMed and Science Direct. A systematic review of published studies following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 was conducted. The protocol of this review was registered at PROSPERO. There were 9 selected randomized controlled trials with a total of 1935 patients were included. The analysis found there was significantly reduction in HbA1c (Mean differences [MD]: -0.67; 95% CI: -1.10 - -0.23; p = 0.003), weight loss (Mean differences [MD]: -2.85; 95% CI: -3.23 – -2.48; p < 0.00001), and fasting blood glucose (Mean differences [MD]: -1.23; 95% CI: -1.66 – -0.80; p < 0.00001). The conclusion obtained from the analysis that the effect of orlistat administration demonstrates significant reductions in HbA1c, body weight, and fasting blood glucose levels. It may have a benefical intervention for managing T2DM with obesity or overweight.
Co-Authors El-Ma’i, Zaha Habibah, Almas Talida Hanifullah, Ardan Mulyarajasa Mas'udi, Achmad Fayyad Murteza, Faiq Permatasari, Azmil Wulandhari